Press Releases

Acticor Biotech first-in-human clinical trial in healthy volunteers

Paris, October 17th, 2017 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and myocardial infarction, today announced the agreement of Dutch Authorities for the initiation of a phase I clinical trial in healthy volunteers with its drug candidate, ACT017. ACT017 is a humanized fragment of […]
Read more

Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum

Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum Phase 1 to start in October 2017 Paris, May 18th, 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, announced today that it has received its second payment from Mediolanum, triggered by […]
Read more

Acticor Biotech has selected its Contract Research Organisation to manage Clinical Study Phase I

The first-in-human study with ACT017 will be conducted at QPS facilities in Groningen, the Netherlands. Paris, February 23rd, 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it selected its CRO (Contract Research Organization) to manage its clinical study phase I. The first-in-human study with ACT017 […]
Read more

Acticor Biotech Secures €1,5M new funding from CapDecisif Management

To accelerate the clinical study of ACT-017, for the emergency treatment of stroke Paris, February 7th 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it has raised €1,5M from CapDecisif Management. Acticor Biotech had already secured €1,4M in the first closing, which brings the total […]
Read more

Stroke company Acticor Biotech and Mediolanum announce a Research Collaboration Agreement

For ACT017, a « first in class » antithrombotic treatment for Acute Ischemic Stroke. Paris, Milan, on October 14, 2016 – Acticor Biotech SAS and Mediolanum farmaceutici S.p.A., today announced that they have entered into a research collaboration agreement for Acticor’s project ACT017, a humanized antibody Fragment (Fab). Under the terms of the agreement, Mediolanum […]
Read more

€1.4 million capital increase by Acticor Biotech

Funding used to step up development of its first-in-class drug candidate for the emergency treatment of strokes Paris, 11 July 2016 – Acticor Biotech, biotechnology company agent without bleeding risk for the emergency treatment of ischemic strokes, has just completed a €1.4 million capital increase. The funds were raised from investors via the Anaxago crowdfunding platform which is […]
Read more
Page 1 of 212